Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

August 11, 2017: By Jon Swedien

ZeissCarl Zeiss Meditec’s revenues for Q3-2016/17 were €277.2 million ($325.8 million, as of Aug. 10, 2017), the German company reported Aug. 7.

That marks a 7.5 percent increase over the company’s Q3-2015/16 revenues.

Zeiss’ revenues during the first nine months of its 2016/17 fiscal year totaled €864.7 million ($1 billion, as of Aug. 10, 2017), marking an 8.3 percent (7.2 percent, cc) increase over the same three quarters from the previous year, Zeiss said.

Ophthalmology sales lead the way for much of the growth, the company said.

Zeiss’ ophthalmic devices strategic business unit recorded €639.9 million ($752 million, as of Aug. 10, 2017), in revenues during the first nine month of Zeiss’ current fiscal year, the company said.

That marks a 9.2 percent (82 percent, cc) increase over the first nine months of the company’s previous fiscal year, Zeiss said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022